[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Mannkind Corp (MNKD)

Mannkind Corp (MNKD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,087,504
  • Shares Outstanding, K 308,950
  • Annual Sales, $ 348,970 K
  • Annual Income, $ 5,860 K
  • EBIT $ 43 M
  • EBITDA $ 56 M
  • 60-Month Beta 1.04
  • Price/Sales 3.14
  • Price/Cash Flow 57.37
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 105.03% (+15.52%)
  • Historical Volatility 72.87%
  • IV Percentile 26%
  • IV Rank 12.64%
  • IV High 500.78% on 10/09/25
  • IV Low 47.76% on 12/17/25
  • Expected Move (DTE 5) 0.34 (9.66%)
  • Put/Call Vol Ratio 0.40
  • Today's Volume 2,935
  • Volume Avg (30-Day) 2,789
  • Put/Call OI Ratio 0.33
  • Today's Open Interest 86,176
  • Open Int (30-Day) 78,614
  • Expected Range 3.18 to 3.86

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $0.00
  • Number of Estimates 3
  • High Estimate $0.01
  • Low Estimate $-0.03
  • Prior Year $0.00
  • Growth Rate Est. (year over year) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.55 +38.04%
on 04/10/26
4.29 -17.95%
on 05/06/26
+0.91 (+34.87%)
since 04/08/26
3-Month
2.23 +57.85%
on 03/27/26
6.05 -41.82%
on 02/10/26
-2.26 (-39.10%)
since 02/06/26
52-Week
2.23 +57.85%
on 03/27/26
6.51 -45.93%
on 01/08/26
-1.11 (-23.97%)
since 05/08/25

Most Recent Stories

More News
MannKind: Q1 Earnings Snapshot

MannKind: Q1 Earnings Snapshot

MNKD : 3.52 (-0.85%)
MannKind Reports First Quarter 2026 Financial Results and Provides Business Update

Q1 updates: Q1 2026 total revenues of $90.2M, +15% vs. Q1 2025 Built out launch infrastructure and aligned field-based teams for upcoming launches Settlement of senior convertible notes of $36.3M...

MNKD : 3.52 (-0.85%)
MannKind Announces Ralinepag Dry Powder Inhalation (DPI) Program to be Pursued for Pulmonary Hypertension and Fibrotic Lung Diseases

The formulation is being developed in collaboration with United Therapeutics Corporation  United Therapeutics made an additional $5 million payment to MannKind to support the rapid advancement of ralinepag...

MNKD : 3.52 (-0.85%)
UTHR : 564.94 (-0.74%)
MannKind's Pediatric Afrezza Decision Could Redefine Its Commercial Identity

Barchart Research What to Expect from MNKD Earnings MNKD Generated May 5, 2026 Current Price $2.86 EPS Estimate $$-0.02 Consensus Rating Strong Buy Average Move 4.70% MannKind's Pediatric Afrezza Decision...

MNKD : 3.52 (-0.85%)
MannKind to Report First Quarter 2026 Financial Results on May 6, 2026

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a biopharmaceutical company dedicated to transforming chronic disease care through...

MNKD : 3.52 (-0.85%)
MannKind to Present New Data From Pediatric and Adult Studies of Afrezza® at ATTD 2026

Presentations highlight real‑world dosing and titration patterns in youth, and post‑prandial glucose management strategies using inhaled insulin in both adults and youth with T1D Data to be featured...

MNKD : 3.52 (-0.85%)
MannKind Announces Settlement of Convertible Senior Notes

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) today announced the settlement of the remaining $36.3 million aggregate principal...

MNKD : 3.52 (-0.85%)
MannKind to Participate in Upcoming Investor Conferences

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , announced today its attendance at two upcoming investor conferences, at which...

MNKD : 3.52 (-0.85%)
MannKind: Q4 Earnings Snapshot

MannKind: Q4 Earnings Snapshot

MNKD : 3.52 (-0.85%)
MannKind Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Q4 2025 revenues of $112M, +46% vs. Q4 2024 Furoscix ® Q4 2025 net sales of $23M, +91% vs. Q4 2024 Afrezza ® Q4 2025 net sales of $23M, +25% vs. Q4 2024 2025 full year revenues...

MNKD : 3.52 (-0.85%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength is above 70%. The market is in overbought territory. Watch for a potential trend reversal.

See More Share

Business Summary

Mannkind Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for diseases such as diabetes, cancer, inflammatory and autoimmune diseases. The Company's lead product, the Technosphere Insulin System, consists of the Company's dry-powder...

See More

Key Turning Points

3rd Resistance Point 3.95
2nd Resistance Point 3.81
1st Resistance Point 3.67
Last Price 3.52
1st Support Level 3.39
2nd Support Level 3.25
3rd Support Level 3.11

See More

52-Week High 6.51
Fibonacci 61.8% 4.88
Fibonacci 50% 4.37
Fibonacci 38.2% 3.86
Last Price 3.52
52-Week Low 2.23

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.